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The short and one-year outcome of 
transcatheter Patent Ductus Arteriosus 
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TRANSCATHETER 
CLOSURE OF PDA
failing to grow adequately, developing respiratory distress, and 
having feeding difficulties, tachypnoea, tachycardia and hepa-
tomegaly. The degree to which one is affected depends on the 
size of the PDA, as well as the PVR. Smaller defects may 
remain relatively asymptomatic, however, there is a significant 
lifetime risk of repeated chest infections, pulmonary hyper-
tension and infective endocarditis precipitated by endothelial 
damage caused by the turbulent flow. Closure of the defect is 
indicated in all children with defects causing any degree of 
heart failure, as well as those at risk of infective endocarditis. 
This includes all patients with the typical continuous or 
“machinery” murmur generated by a PDA. 
In 1939, the first successful cardiac surgical procedure, ligation 
of a PDA, was reported and became a routine procedure 
shortly thereafter.(4) Transcatheter closure, however, was first 
described by Portsman, et al. in 1967, with rapid development 
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INTRODUCTION
During foetal life, the ductus arteriosus is a normal and essen-
tial structure that connects the pulmonary artery to the 
descending aortic arch. Its function is to divert blood away from 
the pulmonary bed while the foetus is intrauterine. 
At delivery, cord clamping, and lung expansion causes a systemic 
rise in oxygen saturation, pulmonary vasodilatation and a drop 
in pulmonary vascular resistance, leading to a sudden reversal of 
flow in the ductus arteriosus from right to left to left to right. 
The ductus arteriosus in the foetus is large, with a diameter 
approximating that of the descending aorta. At birth, the rise in 
systemic arterial oxygen tension and a decrease in circulating 
prostaglandin E2 levels (which were being produced by the 
placenta) trigger ductal constriction, which begins within 10 - 
15 hours after delivery. Closure begins from the pulmonary end 
to the aortic end and is usually complete by 2 - 3 days of age. 
Patent ductus arteriosus (PDA) occurs when the ductus 
arteriosus fails to close spontaneously shortly after birth. It 
accounts for about 6% - 11% of all congenital heart defects.(1) 
A strong association between prematurity and patent ductus 
arteriosus has been described.(2,3)
A PDA causes a drop in the pulmonary vascular resistance 
(PVR) resulting in increasing left to right shunting. If the PDA is 
large, this results in increased pulmonary blood flow and 
reduced aortic flow. This causes cardiac failure with infants 
Background: Transcatheter closure of patent ductus 
arteriosus is a common intervention worldwide. A 
review of the outcomes of patients undergoing this pro-
cedure was undertaken at a central hospital in Durban, 
South Africa.
Methods: Retrospective observational descriptive study 
of the short (<1 year) and long-term (>1 year) effi cacy 
and safety of patients who underwent transcatheter 
closure of PDA from January 2010 - December 2015 at 
Inkosi Albert Luthuli Central Hospital (IALCH), Durban, 
KwaZulu-Natal. 
Results: Over the 5 years, 181 patients underwent car-
diac catheterisation for PDA closure: 170 (93.9%) had 
successful percutaneous closure, and 11 (6.07%) required 
surgical ligation. Mean age was 30.2 ± 9.7 months, weight 
11.2kg ± 3.6kg, PDA diameter on echocardiography 
was 3.64mm (SD ± 0.97mm), fl uoroscopy time 13.66 
minutes (SD ± 4.37min) and radiation dose 468.61 
microGrays (SD ± 149.9microGrays). Devices used 
included the Amplatzer Duct Occluder (ADO) I, ADO II, 
ADO II AS, Cera, Occlutech, detachable coils and vas-
cular plugs.
Twenty-fi ve patients (15%) had complications (6 major: 
2 device embolisation, 1 blood loss and 3 pulse loss).
Conclusion: Percutaneous PDA closure at IALCH, South 
Africa, had a comparable level of safety and effi cacy to 













and refinement of devices used occurring over the next 3 
decades.(5) Echocardiographic advancement allowed reliable 
diagnosis of the PDA as well as evaluation of the anatomy and 
size of the duct by a non-invasive method. The limitations of 
echocardiography are that it is operator dependent and 
requires skill and experience. Angiography further assists in 
delineating size and anatomy with more accuracy. However, it 
carries the burden of being an invasive procedure, as well as 
requiring exposure to radiation.
PDA may vary in size and shape. Some are funnel-shaped, 
others tubular, others with no length at all (aorto-pulmonary 
window type), while others may have more complex mor-
phology with multiple constrictions. This heterogeneity makes 
it impossible to use a single device to close every patent 
ductus arteriosus. Thus, different devices may be required for 
differing morphologies and sizes of defects. 
Krichenko, et al. classified patent ductus arteriosus into 5 
different types based on a lateral descending thoracic aorto-
gram.(6) (Figure 1). While not universally accepted, the classi-
fication may assist in decision-making regarding choice of device 
as well as expected complications during device placement.
The commonly described complications specif ic to tran-
scatheter closure of PDA include a residual shunt, left pul-
monary artery obstruction, protrusion of device into the aorta, 
and embolisation of the device. The incidence increases with 
certain types and size ducts and with the use of certain devices, 
specifically coils for occlusion. Other complications may be 
related to cardiac catheterisation in general, and include vessel 
damage, myocardial perforation and arrhythmias. Anaesthetic 
complications can also be expected.
The AmplatzerTM devices first implanted in 1996(7) have since 
been shown to be safe, effective and relatively easy to use 
with the ability to safely close most types of PDA.(8-19) Similar 
devices subsequently developed have demonstrated similar 
outcomes. Prior to the development of the Amplatzer device, 
detachable coils were the most commonly used device. These 
were, however, generally only suitable for smaller PDAs with a 
higher risk of embolisation and residual leaks. In recent years, 
however, other devices have become available, increasing the 
range of patients who can be offered closure. 
The aim and objective of this study was to assess the immediate 
and one-year safety and efficacy of percutaneous closure of 
patent ductus arteriosus in patients presenting to the Paediatric 
FIGURE 1: Krichenko Criteria.
Krichenko angiographic classification of patent ductus arteriosus (PDA)
Type A: conical
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Cardiology Unit at Inkosi Albert Luthuli Central Hospital 
(IALCH), Durban, South Africa, between January 2010 and 
December 2015.
The hospital is the only government-run hospital providing 
paediatric cardiology services in the province. Eighty-five per-
cent of the province’s 11 million population are dependent on 
public health services. Thirty to 40 transcatheter closures of 
PDA are performed annually at Inkosi Albert Luthuli Central 
Hospital presently.
The purpose of this study was to document the patient pro-
file, device use trends, as well as efficacy and safety of trans-
catheter closure of PDA at this institution. 
METHODOLOGY
Study design & population
A descriptive retrospective chart review (using the Meditech 
electronic database) of all patients who presented to the 
Paediatric Cardiology Unit at the Inkosi Albert Luthuli Central 
Hospital, Durban, South Africa, was performed. One hundred 
and eighty-one of these patients (age 4 months - 372 months) 
who underwent percutaneous transcatheter closure of their 
PDA according to the established criteria for occlusion, from 
January 2010 - December 2015, were retrieved.
Ethics approval was obtained from the Biomedical Research 
Ethics Committee, Department of Health, and IALCH Medical 
Manager.
Patients who had surgical closure of PDA without attempted 
transcatheter closure were excluded from the study.
Data capturing and analysis 
Patient demographics and other variables related to the inter-
vention were captured in a data collection sheet and laid out 
on an Excel spread sheet for analysis. The variables included 
age, gender, weight, preterm/term, birth weight, PDA size on 
echocardiography and angiography, fluoroscopy time and 
radiation exposure dose (contrast dose was not recorded) and 
type of device used. Krichenko classification (A, B, C, D, E)(6) 
was used to record the anatomical type of the patent ductus 
arteriosus. Angiography post deployment was used to deter-
mine the immediate outcome. This was classified as complete 
closure, small residual leak, large leak or unsuccessful closure 
requiring surgical ligation. Post-procedure results were docu-
mented by echocardiography at 1 day, 6 weeks, 1 year and, 
where applicable, beyond 1 year at 1-year intervals. Compli-
cations were divided into major and minor. 
Quantitative data were summarised as mean and standard 
deviation and/or the median and range depending on the 
frequency distribution. Categorical data were reported as fre-
quencies and percentages.
Major and minor complications were reported by age, gesta-
tion, weight and device type and compared using a Chi Square 
test or Fisher’s exact test as appropriate. Efficacy of device 
closure was compared using a Chi-Square or Fisher’s exact test.
Data were analysed using Stata v13 statistical software and a 
p-value of <0.05 was considered statistically significant.
PATENT DUCTUS ARTERIOSUS DEVICE 
OCCLUSION PROCEDURE
The presence and size of the PDA was confirmed by physical 
examination and echocardiography on day of admission and 
was recorded. Written consent was obtained from the legal 
guardians/patients for the intervention after fully explaining the 
procedure.
The patient had either general anaesthesia or sedation with 
midazolam and ketamine, which were the most common agents 
used. General anaesthesia was generally reserved for selected 
patients at risk for upper airway obstruction, such as those 
with Trisomy 21. General anaesthesia could not be used on 
every patient due to limitations in the availability of anaes-
thetic services.
PDA closure method and standard procedure via an arterial 
or venous access usually via the femoral vessels, was used.(7) 
The PVR and left to right shunt were usually measured during 
the procedure. Initially PDA closure was routinely performed 
with a complete haemodynamic study, however it is now 
reserved for specific sitiuations. The appropriate device type 
and size to be used was based on the measurements of 
the PDA on angiography, which included: the narrowest point, 
the ampulla, as well as the length and shape of the duct. The 
size of the device used varied according to the device. For 
the Amplatzer Occluder, it is normally 1mm - 2mm larger than 
the narrowest duct diameter.(20)
Pulmonary deployment was used for most patients, while for 
certain devices and in certain patients, aortic deployment 
was used. After placement of the device, the correct position 
was ascertained using angiography and echocardiography. 
Only then was the device released. 
The patients were monitored during and after the procedure. 
Monitoring was continued in the paediatric ward overnight for 
complications, including haemorrhage, pulse loss, hypotension 
or arrhythmias. The patients were then usually discharged the 
next day after confirming echocardiographically, clinically and 
radiologically that the device was in the correct position and 
that the PDA was closed. 
Patients were then followed up at 6 weeks and 1-year post 
procedure. Subsequent follow up was only performed in 













ciated cardiac abnormalities requiring follow up, or gradients in 




One hundred and 81 patients were identified who fulfilled the 
criteria for inclusion during the 6-year period, January 2010 - 
December 2015. Fifty-two were male (28%) and 129 were 
female (72%). Age range was 4 months - 372 months.
In terms of gestational age at birth, 121/181 (66.8%) were term 
deliveries. Pre-term deliveries accounted for 57/181 (31.5%), 
while in 3 (1.7%) birth gestational age was not recorded.
Characteristics of patent ductus arteriosus: 
The Krichenko criteria were used to classify the patent ductus 
arteriosus shapes from A-E(6) (Figure 1). Type A predomi-
nated, with a total of 110 (60.8%), with type D being the least 
common (Table I). 
The mean size of the PDAs was 3.64mm (SD ± 0.97mm), as 
measured by echocardiography.
Types of devices used
Amplatzer Device Occluder (ADO) I was the most commonly 
used device, followed by ADO II, ADO II AS, and others – 
namely Cera, Occlutech, vascular plugs and detachable coils 
(Table II and Table III). The infrequent use of the other devices 
is attributed to their availability only from 2012.
Radiation exposure 
In 2010, the fluoroscopy time and radiation dose were not 
included in the patient record. Of the 162 patients with ade-
quate records, mean fluoroscopy time was 13.66 minutes (SD 
± 4.37min) and radiation exposure 468.61 microGrays (SD ± 
149.9microGrays). The contrast dose was not recorded.
Patent ductus arteriosus closure rates 
Of the 181 patients, 170 (93.9%) had successful closure of 
patent ductus arteriosus. In 11 patients (6.1%), closure was not 
achieved due to either patent ductus arteriosus size or 
characteristics such as impingement into the aorta or a left 
pulmonary artery that made it difficult to close percutaneously. 









ADO I (Amplatzer I), ADO II (Amplatzer II), ADO II AS (Amplatzer II 
additional sizes).
TABLE I: Types of PDA according to Krichenko criteria.
Type of PDA Total Successful closure 
Type A 110 108
Type B 10 8
Type C 18 12
Type D 7 6
Type E 18 18
NA 18 18
NA = not available.
TABLE III: Different types of devices.
Amplatzer Duct Occluder I (ADO I)
Amplatzer Duct Occluder II (ADO II)
Amplatzer Duct Occluder II Additional 
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DISCUSSION
Transcatheter closure of patent ductus arteriosus is widely used 
with excellent outcomes. Multiple reports both locally and 
internationally have shown effectiveness and safety (mean 
92%), with minimal morbidity (mean 23%).(8,9,14,18,20) World-
wide, the tendency has been, where possible, to favour tran-
scatheter closure over surgical ligation, as it carries less mor-
bidity and mortality.(17,19,21) The patients could be discharged 
the next day after ascertaining the position of the device by 
echocardiography.
This 5-year review demonstrated efficacy and safety compa-
rable to reports from other centres 
Complications were encountered in 15% of patients with the 
majority classified as minor (Table V). This is comparable to 
local as well as international studies (11% - 23%).(7,8,9,14,17,20) 
Sedation-related hypoventilation or airway obstruction requir-
ing manual ventilation and/or oxygen administration was the 
most frequently encountered, however, these were addressed 
rapidly with no neurological or other sequelae. There was no 
death reported during the intervention in our study period. 
Performing these procedures under general anaesthesia would 
likely reduce the incidence, however, the availability of general 
anaesthesia is currently limited at this centre and cannot be 
offered for all patients undergoing cardiac catheterisation. 
Pulse loss as documented in three patients could be avoided 
by performing the procedure using only venous access. This 
requires significant reliance on echocardiographic assessment of 
device position, and is beginning to be implemented in the 
centre, particularly for smaller patients. 
The mean fluoroscopy time measured was 13.66 minutes (SD 
± 4.37min) and radiation exposure 468.61 microGrays (SD ± 
149.9microGrays). The dose of radiation was not mentioned 
in other studies, but the duration was comparable or lower 
than local studies (13 - 23 minutes), but more when compared 
to some international studies.(9,18,22) This could be explained 
by the fact that the hospital is a training centre with trainees 
generally requiring a longer time for procedures. Complete 
haemodynamic studies were also routinely performed, initially 
increasing fluoroscopy time. Contrast dose was not captured.
Current manufacturer recommendations for practically all 
PDA devices are that they be used in patients older than 6 
months and weighing more than 5 kilograms. However, a 
number of recent studies have demonstrated that device 
closure can be safely achieved in patients younger than 6 
months and weighing even under 1 kilogram.(23,24) The risk of 
adverse events was higher in this age group and the benefit 
of percutaneous closure over surgical ligation needs to be 
carefully weighed.(17) During the study period, 5 patients were 
Of those who had successful closure: 130/170 (76.4%) had 
complete closure on day of catheterisation. By day 1, 85.3% 
had achieved complete closure and by 6 weeks this increased 
to 94.7%. At 1 year follow up, 98.2% had complete closure, 
while 3 had residual leaks (1.76%). Patients with complete 
closure and no further cardiac complications were generally 
discharged from the clinic at 1 year. 
The 3 patients with residual flow were followed up beyond 
1 year. An Occlutech device was used in two and an ADO 1 in 
the other. No further intervention was performed, as the leaks 
were small with no audible murmur. 
Complications 
Twenty-five patients had recorded complications, most of 
which were classif ied as minor, the most common being 
desaturation from sedation requiring manual bagging and/or 
oxygen administration (Table IV). Six patients had major com-
plications: 2 had device embolisation which were retrieved 
percutaneously and replaced with an alternative device: 1 with 
an ADO I (PDA was then closed with a larger ADO I) and 
the other with an ADO II AS (an ADO I was then used to 
close the PDA); 1 suffered blood loss needing a blood trans-
fusion and 3 had pulse loss, with 2 requiring heparin and 
1 tenecteplase. No mortality from percutaneous transcatheter 
closure of patent ductus arteriosus was reported in this 5-year 
period.
Minor complications under “Other” included mild hypoten-
sion, mild temperature increases post procedure, and mild 
intraprocedural upper airway obstruction or hypoventilation 
requiring bag mask ventilation or oxygen.
Association of complication with 
various parameters
Age, weight, gestation and type of device used were compared 
with the complications encountered in the study. None of the 
data obtained were statistically significant (Table V), likely due 
to the small study number.
TABLE IV: Complications of transcatheter closure of 
patent ductus arteriosus.
Major Minor N = 25
PDA spasm 3
Blood loss requiring transfusion 1
Device embolisation 2
SVT 1
Pulse loss requiring heparin/tenecteplase 3
Other* 15













under 6 months of age or under 5 kilograms at the time of 
the procedure. None had complications. Based on current 
practice and as further experience with device closure in 
younger infants is obtained, both nationally and internationally, 
it is expected that device closure will be increasingly extended 
to these patients. Female predominance in our cohort is similar 
to that from other reports.(14) 
The Amplatzer family of devices were the most commonly 
used. This was largely due to these devices together with 
detachable coils, being the only available devices until 2012. It 
would be expected that frequency of use of alternative devices 
would increase with time. Cost differences, suitability for dif-
ferent anatomy, as well as continued availability of various 
devices, may also play a role in types of device used. A direct 
comparison of safety and efficacy between devices was not 
possible in this study.
LIMITATIONS OF THIS STUDY
The primary limitations of this study were the retrospective 
nature allowing only previously recorded data to be obtained, 
as well as the relatively small sample size, as can be expected 
from a single centre review.
CONCLUSION
Transcatheter percutaneous closure of patent ductus arteriosus 
at this centre appeared to be safe, effective and comparable 
to other reports in the literature. This study adds to the body 
of literature available on the current status of percutaneous 
PDA closure both locally and internationally.
Conflict of interest: none declared.
TABLE V: Complications according to age/weight/gestational age/device type.
Yes No
Number % Number %
Age/months (p-value = 0.9)
≤6 (6) 0 0 6 100
6 - 372 (175) 25 14.2 150 85.7
Total (181) 25 13.8 156 86.1
Weight/kg (p-value = 0.4)
<5 (4) 0 0 4 100
5.01 - 54 (177) 24 13.6 153 86.4
Total (181) 25 13.8 156 86.1
Gestation (p-value  = 0.1)
Pre-term (57) 11 19.2 46 80.7
Term (122) 14 11.4 108 88.5
Not recorded (2) 0 0 2 100
Type of device (p-value = 0.7)
ADO I (135) 17 12.6 117 86.7
ADO II (17) 3 17.6 13 76.4
Others (29) 3 10.3 26 89.7
Total (181) 25 13.8 156 86.1
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